A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
Study of IMC-F106C Alone and in Combination With Checkpoint Inhibitors in Participants with Advanced Cancers
Sponsor: Immunocore Ltd
Enrolling: Male and Female Patients
IRB Number: AAAS8402
U.S. Govt. ID: NCT04262466
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This is a research study to determine how safe and effective a new treatment, called IMC-F106C, is for treating advanced cancers. This study is the first time the study drug is being tested in people. IMC-F106C has been developed to treat cancer by activating the body's own immune system to fight the tumor. The study drug has 2 parts. The first part, called a T cell receptor, sticks very tightly to tumor cells that make markers called HLA-A*02:01 and PRAME. The second part, called anti-CD3 scFv, sticks to a T cell (a type of white blood cell that helps protect your body against disease). IMC F106C makes the T cell stick to the cancer cell, which then sends a signal to attack the tumor. Cancers include: Bladder cancer, breast cancer, gynecologic cancer, ovarian cancer, uterine (endometrial) cancer, kidney cancer/adrenal cancer, lung cancer, skin cancer, and melanoma.
Benjamin Izar, MD
Do You Qualify?
Are you at least 18 years of age? Yes No
Are you able to perform every day tasks independently? Yes No
Have you been diagnosed with advanced cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator